Metabolic disease and the liver: A review.

Autor:	Vargas M; Program of Graduate Science in Gastroenterology and Hepatology, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Rio Grande do Sul, Brazil., Cardoso Toniasso SC; School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil., Riedel PG; School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil., Baldin CP; Program of Graduate Science in Gastroenterology and Hepatology, Clinicas Hospital of Porto Alegre, Porto Alegre 90410000, Brazil., Dos Reis FL; School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil., Pereira RM; Medicine Faculty Federal University of Rio Grande do Sul, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil., Brum MCB; School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil., Joveleviths D; Program of Graduate Science in Gastroenterology and Hepatology, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Rio Grande do Sul, Brazil. dvorajov@gmail.com., Alvares-da-Silva MR; Division of Gastroenterology and Hepatology, Clinicas Hospital of Porto Alegre, Porto Alegre 90035007, Brazil.
Jazyk:	angličtina
Zdroj:	World journal of hepatology [World J Hepatol] 2024 Jan 27; Vol. 16 (1), pp. 33-40.
DOI:	10.4254/wjh.v16.i1.33
Abstrakt:	Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, with an estimated prevalence of 31% in Latin America. The presence of metabolic comorbidities coexisting with liver disease varies substantially among populations. It is acknowledged that obesity is boosting the type 2 diabetes mellitus "epidemic," and both conditions are significant contributors to the increasing number of patients with MASLD. Non-alcoholic steatohepatitis represents a condition of chronic liver inflammation and is considered the most severe form of MASLD. MASLD diagnosis is based on the presence of steatosis, noninvasive scores and altered liver tests. Noninvasive scores of liver fibrosis, such as serum biomarkers, which should be used in primary care to rule out advanced fibrosis, are simple, inexpensive, and widely available. Currently, guidelines from international hepatology societies recommend using noninvasive strategies to simplify case finding and management of high-risk patients with MASLD in clinical practice. Unfortunately, there is no definite pharmacological treatment for the condition. Creating public health policies to treat patients with risk factors for MASLD prevention is essential. Competing Interests: Conflict-of-interest statement: All the authors declare that they have no conflicts of interest. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu